Contents 4 dk okuma

Claim and source comparison

Compared abstracts of Cansev 2007, Kondo 2011, Babb 2002, Cochrane 2020, 36-month LipiDiDiet and the 2026 stage-stratified meta-analysis. Mixture effects were not assigned to one ingredient; this limited reading is not complete clinical or independent medical review.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Animal study

Cansev and Wurtman (2007) reported increased brain phosphatide and synaptic protein measures in gerbils given DHA or EPA with uridine. This animal biochemistry study does not establish human memory enhancement or clinical benefit from new synapses.

Gerbil brain lipids and synaptic proteins do not establish clinical benefit from new synapses in humans. A choline-containing diet/omega-3/UMP experiment cannot establish a healthy-human “Mr. Happy Stack,” safe ratio or BDNF effect.

Source 1 · Abstract read

Human case report / case review

Kondo et al. (2011) reported 6 weeks of open-label uridine in 7 adolescents with bipolar depression. There was no placebo group; symptom changes do not establish efficacy or generalize to memory enhancement in healthy people.

The open series of seven was neither randomized nor placebo-controlled. Symptom change does not establish efficacy, standard adolescent treatment or memory enhancement in healthy people; it does not provide a self-directed psychiatric protocol.

Source 3 · Abstract read

Human randomized controlled trial

Babb et al. (2002) studied phosphorus MRS measures with citicoline, 500 mg/day; an initial 6-week treatment was followed by citicoline or placebo for a second 6 weeks. The tested substance was citicoline, not uridine or UMP.

Phosphodiester/MRS measurement is not a count of new synapses or evidence of uridine’s cognitive efficacy. An experiment using another precursor cannot be presented as a randomized uridine trial.

Source 2 · Abstract read

Systematic review / meta-analysis

Cochrane (2020) evaluated 3 randomized Souvenaid trials with 1097 participants. Dementia progression risk was not clearly reduced at 24 months in prodromal Alzheimer’s disease (311 participants; RR 1.09, 95% CI 0.82–1.43); general cognitive benefit was not convincing.

Souvenaid/Fortasyn Connect contains choline, omega-3 and other nutrients alongside UMP; it is not an isolated UMP trial. Mixed stage-specific findings and limited safety data do not allow effects to be assigned to one ingredient or healthy people.

Source 4 · Abstract read

Human randomized controlled trial

In LipiDiDiet’s 36-month report, 311 participants were initially randomized; 162 completed and 81 had month-36 data eligible for efficacy analysis. The multinutrient product’s NTB difference was 0.212 (95% CI 0.044–0.380; p=0.014).

The positive extension finding must be interpreted with substantial attrition and exclusion of data after starting open-label product or Alzheimer medication. It cannot be attributed to isolated UMP, healthy people or prevention of dementia by UMP alone.

Source 5 · Abstract read

Systematic review / meta-analysis

A 2026 stage-stratified meta-analysis found 4 eligible trials; 3 entered quantitative synthesis (906 participants). The exploratory pooled cognitive effect was not significant (SMD 0.08, 95% CI −0.09–0.26; p=0.35); some early-stage and extension findings differed.

Exploratory pooling across stages, few studies, lack of replication across stages and manufacturer support require caution. A selected mixture outcome does not establish UMP’s isolated efficacy or a safe combination ratio.

Source 6 · Abstract read

Our evidence and source methodology

Uridine Monophosphate: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Uridine Monophosphate?

Uridine is a nucleoside involved in membrane synthesis; UMP is its phosphorylated form. Synaptic findings with choline and DHA mostly come from animals; “Mr. Happy Stack” is not an established cognitive protocol for healthy humans.

Mechanism of Effect

Cansev and Wurtman (2007) reported increased brain phosphatide and synaptic protein measures in gerbils given DHA or EPA with uridine. This animal biochemistry study does not establish human memory enhancement or clinical benefit from new synapses.

Gerbil brain lipids and synaptic proteins do not establish clinical benefit from new synapses in humans. A choline-containing diet/omega-3/UMP experiment cannot establish a healthy-human “Mr. Happy Stack,” safe ratio or BDNF effect.

Clinical Evidence

Kondo et al. (2011) reported 6 weeks of open-label uridine in 7 adolescents with bipolar depression. There was no placebo group; symptom changes do not establish efficacy or generalize to memory enhancement in healthy people.

The open series of seven was neither randomized nor placebo-controlled. Symptom change does not establish efficacy, standard adolescent treatment or memory enhancement in healthy people; it does not provide a self-directed psychiatric protocol.

Babb et al. (2002) studied phosphorus MRS measures with citicoline, 500 mg/day; an initial 6-week treatment was followed by citicoline or placebo for a second 6 weeks. The tested substance was citicoline, not uridine or UMP.

Phosphodiester/MRS measurement is not a count of new synapses or evidence of uridine’s cognitive efficacy. An experiment using another precursor cannot be presented as a randomized uridine trial.

Cochrane (2020) evaluated 3 randomized Souvenaid trials with 1097 participants. Dementia progression risk was not clearly reduced at 24 months in prodromal Alzheimer’s disease (311 participants; RR 1.09, 95% CI 0.82–1.43); general cognitive benefit was not convincing.

Souvenaid/Fortasyn Connect contains choline, omega-3 and other nutrients alongside UMP; it is not an isolated UMP trial. Mixed stage-specific findings and limited safety data do not allow effects to be assigned to one ingredient or healthy people.

In LipiDiDiet’s 36-month report, 311 participants were initially randomized; 162 completed and 81 had month-36 data eligible for efficacy analysis. The multinutrient product’s NTB difference was 0.212 (95% CI 0.044–0.380; p=0.014).

The positive extension finding must be interpreted with substantial attrition and exclusion of data after starting open-label product or Alzheimer medication. It cannot be attributed to isolated UMP, healthy people or prevention of dementia by UMP alone.

A 2026 stage-stratified meta-analysis found 4 eligible trials; 3 entered quantitative synthesis (906 participants). The exploratory pooled cognitive effect was not significant (SMD 0.08, 95% CI −0.09–0.26; p=0.35); some early-stage and extension findings differed.

Exploratory pooling across stages, few studies, lack of replication across stages and manufacturer support require caution. A selected mixture outcome does not establish UMP’s isolated efficacy or a safe combination ratio.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

UMP and triacetyluridine are different formulations; equal milligram doses do not imply equal exposure. UMP has not been shown to have superior bioavailability to all forms or the most effective combination with other supplements.

Safety and Side Effects

Uridine in foods or breast milk does not establish safety of high-dose supplements. Small short-term trials cannot establish long-term, pregnancy or multi-supplement combination safety.

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

  • Neuroplasticity: mechanisms, human evidence and research limits

    The brain’s capacity to change does not establish that a supplement renews it. This guide compares synaptic mechanisms with measured human outcomes and explains what learning, exercise and product research can establish, and what remains uncertain.

Sources

  1. Cansev M, Wurtman RJ. (2007). Chronic administration of docosahexaenoic acid or eicosapentaenoic acid, but not arachidonic acid, alone or in combination with uridine, increases brain phosphatide and synaptic protein levels in gerbils. Neuroscience, 148(2), 421–431. PubMed · PMID 17683870
  2. Babb SM, et al. (2002). Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology, 161(3), 248–254. PubMed · PMID 12021827
  3. Kondo DG, et al. (2011). Open-label uridine for treatment of depressed adolescents with bipolar disorder. Journal of Child and Adolescent Psychopharmacology, 21(2), 171–175. PubMed · PMID 21486171
  4. Burckhardt M, et al. (2020). Souvenaid for Alzheimer's disease. The Cochrane database of systematic reviews, 12(12), CD011679. https://doi.org/10.1002/14651858.CD011679.pub2 PubMed · PMID 33320335
  5. Soininen H, et al. (2021). 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 17(1), 29-40. https://doi.org/10.1002/alz.12172 PubMed · PMID 32920957
  6. Han P, et al. (2026). Stage-Dependent Cognitive Effects of a Multinutrient Intervention in Alzheimer's Disease: A Stage-Stratified Meta-Analysis. Journal of Visualized Experiments, (235). https://doi.org/10.3791/72385 PubMed · PMID 42683892

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions